Mylan Inc. (NASDAQ: MYL): Closing price $32.09
On Tuesday, Mylan announced that Judge Katherine Forrest of the United States District Court for the Southern District of New York has dismissed Teva’s lawsuit claiming that Mylan’s abbreviated new drug application for its generic version of Copaxone (glatiramer acetate) infringes four patents held by Teva (U.S. Patent Nos. 66,514,938, 7,074,580, 7,163,802, and 7,615,359).
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Closing price $107.04
Alexion said Tuesday that Soliris (eculizumab), its first-in-class terminal complement inhibitor, has gotten a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products of the European Medicines Agency, to treat neuromyelitis optica, which is a life-threatening, ultra-rare neurological disorder. The positive opinion has now been forwarded to the European Commission for final approval, and publication in the community register. Presently, Soliris is not approved anywhere for the treatment of patients having NMO.
Teva Pharmaceutical Industries (NYSE:TEVA): Closing price $39.41
Israel’s Tax Authority said on Tuesday that the country’s biggest company garnered almost 12 billion shekels, or $3.3 billion, in government tax breaks between 2006 and 2011 as part of a program to boost capital investment. Teva led the list of firms receiving annual tax breaks at 11.78 billion shekels, according to the authority.
SIGA Technologies, Inc. (NASDAQ:SIGA): Closing price $3.30
SIGA said Tuesday that it has attained another important commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr, to the United States Government’s Strategic National Stockpile. With its cumulative delivery of about 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has achieved a crucial requirement of its contract with the Government’s Biomedical Advanced Research and Development Authority, and has qualified for a payment of roughly $79 million for the courses delivered thus far.
Don’t Miss: J&J: A Really Great Quarter or Just a Good One?